Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Oncology in Clinical Practice
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2022 Professor Krzysztof Krzemieniecki Award

Vol 11, No 1 (2015)

Date published: 2015-03-12

Table of Contents

open access

EXPERTS' OPINION

Clinical relevance of therapeutic benefit in anti-cancer drugs assessment

Rafał Zyśk, Maciej Krzakowski, Jacek Jassem, Krzysztof Krzemieniecki, Piotr Potemski, Piotr Wysocki

Guidelines / Expert consensus

Onkol. Prak. Klin 2015;11(1):1-8.
PDF HTML

The algorithm assessing the value of new anticancer drugs — the proposal of the Polish Society of Clinical Oncology and Polish Oncological Society

Maciej Krzakowski, Piotr Wysocki, Jacek Jassem, Krzysztof Krzemieniecki, Piotr Potemski, Rafał Zyśk

Guidelines / Expert consensus

Onkol. Prak. Klin 2015;11(1):9-15.
PDF HTML

WHO position paper on mammography screening

Joanna Didkowska, Urszula Wojciechowska

Guidelines / Expert consensus

Onkol. Prak. Klin 2015;11(1):16-19.
PDF HTML
REVIEW ARTICLES

Palliative care — essential part of multidisciplinary approach in oncology

Jolanta Andrzejuk, Renata Biernacka, Tomasz Lewandowski

Review paper

Onkol. Prak. Klin 2015;11(1):20-25.
PDF HTML
CASE REPORTS

False positive result of beta subunit of hCG testing in a patient with stage IA testicular germ cell tumor during routine follow-up

Aleksandra Łacko, Katarzyna Soter

Case report

Onkol. Prak. Klin 2015;11(1):26-29.
PDF HTML
Onkologia na świecie

Subcutaneous trastuzumab (Herceptin®): A UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer

Russell Burcombe, Steve Chan, Richard Simcock, Kunal Samanta, Fran Percival, Peter Barrett-Lee

Other materials agreed with the Editors

Onkol. Prak. Klin 2015;11(1):30-39.
PDF HTML

Komentarz do pracy: Trastuzumab (Herceptin®) podawany podskórnie: brytyjskie badanie porównujące techniczne aspekty metody z dożylnym leczeniem trastuzumabem u chorych na HER2-dodatniego raka piersi

Piotr Wysocki

Other materials agreed with the Editors

Onkol. Prak. Klin 2015;11(1):40.
PDF HTML

Komentarz do pracy: Trastuzumab (Herceptin®) podawany podskórnie: brytyjskie badanie porównujące techniczne aspekty metody z dożylnym leczeniem trastuzumabem u chorych na HER2-dodatniego raka piersi

Rafał Zyśk

Other materials agreed with the Editors

Onkol. Prak. Klin 2015;11(1):41-42.
PDF HTML

Defining value-driven care in head and neck oncology

Benjamin R. Roman, Mahmoud I. Awad, Snehal G. Patel

Other materials agreed with the Editors

Onkol. Prak. Klin 2015;11(1):43-51.
PDF HTML

Komentarz do pracy: Określenie wartości opieki medycznej w nowotworach głowy i szyi

Romuald Krajewski

Other materials agreed with the Editors

Onkol. Prak. Klin 2015;11(1):52.
PDF HTML

Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system

Rami E. Saade, Ehab Y. Hanna, Diana Bell

Other materials agreed with the Editors

Onkol. Prak. Klin 2015;11(1):53-59.
PDF HTML

Intraoperative radiotherapy for gastrointestinal malignancies: contemporary outcomes with multimodality therapy

Felipe A. Calvo, Claudio V. Sole, Hugo Marsiglia, Eduardo Alvarado, Carlos Ferrer, Brian Czito

Other materials agreed with the Editors

Onkol. Prak. Klin 2015;11(1):60-67.
PDF HTML

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl